Compare DexCom, Inc. (DXCM) vs Okta, Inc. (OKTA) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

OKTA trades at $150.97, down 2.36% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported revenue of $2.61B in 2025, achieving positive net income of $28M after years of losses, and has beaten earnings estimates for three consecutive quarters. Analyst consensus is strongly bullish with 72.55% buy ratings, though the stock trades above the consensus price target of $125.78.

The outlook for OKTA is positive due to robust revenue growth, improving profitability, and strong demand for AI-driven cybersecurity solutions. Key risks include high valuation multiples, intense competition, and sensitivity to enterprise IT spending cycles. The stock presents a growth opportunity but requires monitoring of execution and market sentiment shifts.